Q-omics provides the consensus-scored CDYL-AS1 profile across patient tissues and cancer cell-line models. CDYL-AS1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CDYL-AS1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CDYL-AS1 RNA expression shows 6,987 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, THCA, and LSCC as cancer lineages where CDYL-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDYL-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDYL-AS1 survival associations across molecular data types. CDYL-AS1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDYL-AS1 RNA expression–survival associations across cancer types. High CDYL-AS1 expression shows unfavorable associations in UCEC, ACC, STAD and MESO, but favorable associations in UVM and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CDYL-AS1 RNA expression.
This table summarizes CDYL-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDYL-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDYL-AS1 shows lower tumor expression in THCA, KIRC, KICH and HNSC and higher tumor expression in LUSC and BRCA. The THCA box plot shows higher CDYL-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.102, t-test p < 0.001).
This table shows molecular features associated with CDYL-AS1 in patient tissues and cancer cell lines. In patient samples, CDYL-AS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
